Erleada Demonstrates Statistically Significant and Clinically Meaningful Improvement in Overall Survival Compared to Enzalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer
October 03, 2024
October 03, 2024
NEW BRUNSWICK, New Jersey, Oct. 3 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA reduced risk of death by 23 percent at 24 months compared to enzalutamide
* * *
LISBON, PORTUGAL, October 2, 2024 - Johnson & Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA (apalutamide) provided a . . .
* * *
Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA reduced risk of death by 23 percent at 24 months compared to enzalutamide
* * *
LISBON, PORTUGAL, October 2, 2024 - Johnson & Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA (apalutamide) provided a . . .